FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2798078275> ?p ?o ?g. }

• W2798078275 abstract "Background Early withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST ‐segment elevation myocardial infarction ( STEMI ) given the increased risk of thrombotic complications. This study assessed the frequency, predictors, and clinical impact of early prasugrel cessation in patients with STEMI undergoing primary percutaneous coronary interventions. Methods and Results We pooled patients with STEMI discharged on prasugrel in 2 prospective registries (Bern PCI Registry [ NCT 02241291] and SPUM ‐ ACS (Inflammation and Acute Coronary Syndromes) [ NCT 01000701]) and 1 STEMI trial ( COMFORTABLE ‐ AMI (Comparison of Biomatrix Versus Gazelle in ST‐Elevation Myocardial Infarction) [ NCT 00962416]). Prasugrel treatment status at 1 year was categorized as no cessation; crossover to another P2Y 12 ‐inhibitor; physician‐recommended discontinuation; and disruption because of bleeding, side effects, or patient noncompliance. In time‐dependent analyses, we assessed the impact of prasugrel cessation on the primary end point, a composite of cardiac death, myocardial infarction, and stroke. Of all 1830 included patients (17% women, mean age 59 years), 83% were treated with new‐generation drug‐eluting stents. At 1 year, any prasugrel cessation had occurred in 13.8% of patients including crossover (7.2%), discontinuation (3.7%), and disruption (2.9%). Independent predictors of any prasugrel cessation included female sex, age, and history of cerebrovascular event. The primary end point occurred in 5.2% of patients and was more frequent following disruption (hazard ratio 3.04, 95% confidence interval,1.34–6.91; P =0.008), without significant impact of crossover or discontinuation. Consistent findings were observed for all‐cause death, myocardial infarction, and stent thrombosis following prasugrel disruption. Conclusions In this contemporary study of patients with STEMI , early prasugrel cessation was not uncommon and primarily involved change to another P2Y 12 ‐inhibitor. Disruption was the only type of early prasugrel cessation associated with statistically significant excess in ischemic risk within 1 year following primary percutaneous coronary interventions." @default.
• W2798078275 created "2018-04-24" @default.
• W2798078275 creator A5000190765 @default.
• W2798078275 creator A5019587141 @default.
• W2798078275 creator A5040134218 @default.
• W2798078275 creator A5040563213 @default.
• W2798078275 creator A5045293936 @default.
• W2798078275 creator A5047690226 @default.
• W2798078275 creator A5048050232 @default.
• W2798078275 creator A5051530432 @default.
• W2798078275 creator A5053194091 @default.
• W2798078275 creator A5055357489 @default.
• W2798078275 creator A5060467171 @default.
• W2798078275 creator A5061359562 @default.
• W2798078275 creator A5064844092 @default.
• W2798078275 creator A5066913399 @default.
• W2798078275 creator A5070548943 @default.
• W2798078275 creator A5075035084 @default.
• W2798078275 creator A5085573148 @default.
• W2798078275 creator A5086449617 @default.
• W2798078275 date "2018-04-17" @default.
• W2798078275 modified "2023-09-27" @default.
• W2798078275 title "Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST‐Elevation Myocardial Infarction" @default.
• W2798078275 cites W1582971617 @default.
• W2798078275 cites W1992878638 @default.
• W2798078275 cites W2007221451 @default.
• W2798078275 cites W2020190643 @default.
• W2798078275 cites W2043438355 @default.
• W2798078275 cites W2043964965 @default.
• W2798078275 cites W2048216325 @default.
• W2798078275 cites W2052713441 @default.
• W2798078275 cites W2085615490 @default.
• W2798078275 cites W2087150869 @default.
• W2798078275 cites W2110108344 @default.
• W2798078275 cites W2115824015 @default.
• W2798078275 cites W2122779695 @default.
• W2798078275 cites W2126980526 @default.
• W2798078275 cites W2133536883 @default.
• W2798078275 cites W2135627554 @default.
• W2798078275 cites W2140776066 @default.
• W2798078275 cites W2150798094 @default.
• W2798078275 cites W2150914344 @default.
• W2798078275 cites W2169387542 @default.
• W2798078275 cites W2324839838 @default.
• W2798078275 cites W2494452675 @default.
• W2798078275 cites W2543143993 @default.
• W2798078275 cites W2579869488 @default.
• W2798078275 cites W2614154720 @default.
• W2798078275 cites W2744105079 @default.
• W2798078275 cites W2748517697 @default.
• W2798078275 cites W2752033985 @default.
• W2798078275 cites W4211143229 @default.
• W2798078275 cites W4236531408 @default.
• W2798078275 doi "https://doi.org/10.1161/jaha.117.008085" @default.
• W2798078275 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6015438" @default.
• W2798078275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29654204" @default.
• W2798078275 hasPublicationYear "2018" @default.
• W2798078275 type Work @default.
• W2798078275 sameAs 2798078275 @default.
• W2798078275 citedByCount "9" @default.
• W2798078275 countsByYear W27980782752018 @default.
• W2798078275 countsByYear W27980782752019 @default.
• W2798078275 countsByYear W27980782752020 @default.
• W2798078275 countsByYear W27980782752021 @default.
• W2798078275 countsByYear W27980782752022 @default.
• W2798078275 countsByYear W27980782752023 @default.
• W2798078275 crossrefType "journal-article" @default.
• W2798078275 hasAuthorship W2798078275A5000190765 @default.
• W2798078275 hasAuthorship W2798078275A5019587141 @default.
• W2798078275 hasAuthorship W2798078275A5040134218 @default.
• W2798078275 hasAuthorship W2798078275A5040563213 @default.
• W2798078275 hasAuthorship W2798078275A5045293936 @default.
• W2798078275 hasAuthorship W2798078275A5047690226 @default.
• W2798078275 hasAuthorship W2798078275A5048050232 @default.
• W2798078275 hasAuthorship W2798078275A5051530432 @default.
• W2798078275 hasAuthorship W2798078275A5053194091 @default.
• W2798078275 hasAuthorship W2798078275A5055357489 @default.
• W2798078275 hasAuthorship W2798078275A5060467171 @default.
• W2798078275 hasAuthorship W2798078275A5061359562 @default.
• W2798078275 hasAuthorship W2798078275A5064844092 @default.
• W2798078275 hasAuthorship W2798078275A5066913399 @default.
• W2798078275 hasAuthorship W2798078275A5070548943 @default.
• W2798078275 hasAuthorship W2798078275A5075035084 @default.
• W2798078275 hasAuthorship W2798078275A5085573148 @default.
• W2798078275 hasAuthorship W2798078275A5086449617 @default.
• W2798078275 hasBestOaLocation W27980782751 @default.
• W2798078275 hasConcept C126322002 @default.
• W2798078275 hasConcept C164705383 @default.
• W2798078275 hasConcept C168563851 @default.
• W2798078275 hasConcept C203092338 @default.
• W2798078275 hasConcept C207103383 @default.
• W2798078275 hasConcept C2777028646 @default.
• W2798078275 hasConcept C2777849778 @default.
• W2798078275 hasConcept C2778715236 @default.
• W2798078275 hasConcept C2780400711 @default.
• W2798078275 hasConcept C44249647 @default.
• W2798078275 hasConcept C500558357 @default.
• W2798078275 hasConcept C71924100 @default.
• W2798078275 hasConceptScore W2798078275C126322002 @default.
• W2798078275 hasConceptScore W2798078275C164705383 @default.

• next